Next generation probiotics: Engineering live biotherapeutics

Biotechnol Adv. 2024 Mar 1:108336. doi: 10.1016/j.biotechadv.2024.108336. Online ahead of print.ABSTRACTThe population dynamics of the human microbiome have been associated with inflammatory bowel disease, cancer, obesity, autoimmune diseases, and many other human disease states. An emerging paradigm in treatment is the administration of live engineered organisms, so- called next-generation probiotics. However, the efficacy of these microbial therapies can be limited by the organism's overall performance in the harsh and nutrient-limited environment of the gut. In this review, we summarize the current state of the art use of bacterial and yeast strains as probiotics, highlight the recent development of genetic tools for engineering new therapeutic functions in these organisms, and report on the latest therapeutic applications of engineered probiotics, including recent clinical trials. We also discuss the supplementation of prebiotics as a method of manipulating the microbiome and improving the overall performance of engineered live biotherapeutics.PMID:38432422 | DOI:10.1016/j.biotechadv.2024.108336
Source: Biotechnology Advances - Category: Biotechnology Authors: Source Type: research